COVID-19: How and when to take DRDO's 2DG drug - Check guidelines here freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
DNA Explainer: How to administer 2-DG drug on COVID-19 patients, DRDO guidelines - The oral drug cleared by the Drugs Controller General of India on May 1 for emergency use, is an adjunct therapy to treat severe COVID-19 patients.
New Delhi [India], June 1 (ANI): The Defence Research and Development Organisation's (DRDO) on Tuesday said that the anti-COVID drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.
DRDO issues directions on usage of anti-COVID drug 2-DG
SECTIONS
Last Updated: Jun 01, 2021, 08:40 PM IST
Share
Synopsis
The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May. The first batch of this oral drug, developed by the Defence Research and Development Organisation (DRDO), was released on May 17 by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.
Agencies
The DRDO said the drug is approved for emergency use as adjunct therapy to the standard treatment of COVID-19 patients in the hospital settings.
The Defence Research and Development Organisation`s (DRDO) on Tuesday (June 1) said that the anti-COVID drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.